A5075501994- Monoclonal and Polyclonal Antibodies Research
- Biosimilars and Bioanalytical Methods
- Asthma and respiratory diseases
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Analytical Chemistry and Chromatography
- Protein purification and stability
- Genetic and Kidney Cyst Diseases
- Advanced Biosensing Techniques and Applications
- Allergic Rhinitis and Sensitization
- Cell Adhesion Molecules Research
- Toxin Mechanisms and Immunotoxins
- Pulmonary Hypertension Research and Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- CRISPR and Genetic Engineering
- Dermatology and Skin Diseases
- Research on Leishmaniasis Studies
University of Chicago
2024
United States Military Academy
2023
Merck & Co., Inc., Rahway, NJ, USA (United States)
2023
GlaxoSmithKline (United States)
2011-2021
Bristol-Myers Squibb (United States)
2016
SUNY Downstate Health Sciences University
2005-2009
The 2022 16th Workshop on Recent Issues in Bioanalysis (WRIB) took place Atlanta, GA, USA September 26-30, 2022. Over 1000 professionals representing pharma/biotech companies, CROs, and multiple regulatory agencies convened to actively discuss the most current topics of interest bioanalysis. WRIB included 3 Main Workshops 7 Specialized that together spanned 1 week order allow exhaustive thorough coverage all major issues bioanalysis, biomarkers, immunogenicity, gene therapy, cell therapy...
Sotatercept, a soluble fusion protein comprising the extracellular domain of activin receptor type IIA linked to Fc portion human IgG1, is first‐in‐class signaling inhibitor under development for treatment pulmonary arterial hypertension (PAH). We evaluated antidrug antibody (ADA) and determined effects immunogenicity on pharmacokinetics (PKs), efficacy, safety sotatercept in STELLAR, multicenter, double‐blind phase III trial (NCT04576988) wherein participants with PAH were randomized 1:1...
Mepolizumab, a humanized IgG1 monoclonal antibody that blocks native homodimeric interleukin-5 (IL-5) from binding to the IL-5 receptor, has recently been approved for treatment of severe eosinophilic asthma. Our initial immunogenicity assay method phase I and II studies utilized bridging electrochemiluminescence format with biotin ruthenium-labelled mepolizumab linked by anti-drug antibodies (ADA). We discovered significantly increased in dosed subjects study was form drug-bound complex....
Interleukin-7 (IL-7) signaling modulates T cell activity and is implicated in numerous autoimmune diseases. An anti-IL-7 receptor monoclonal antibody (GSK2618960) biotherapeutic was evaluated healthy subjects for safety, pharmacokinetics (PK), pharmacodynamics (PD) immunogenicity a single-dose escalation phase I study. We found that antibodies against GSK2618960 (i.e., anti-drug or ADA) developed 83% 100% of GSK2618960-treated the 0.6 2.0 mg/kg dose cohorts, respectively. Of ADA positive...